地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:18995651644
邮箱:sales@amyjet.com

Alfa Aesar(阿法埃莎)是一家科研化学品、金属和材料的生产商及供应商,公司产品在各种应用领域的研究和开发中发挥着重要的作用,凭借多年的生产经验,该公司的化学师们掌握了大量的技能和经验,利用从实验室规模到中试工厂再到商业化批量生产的工艺路线,向客户交付出优质的化学产品。Alfa Aesar在全球各地的许多工厂从事化学合成生产。在英国西北部的Heysham工厂是该公司的主要实验室之一,经验丰富的开发和生产团队可交付各种产品,以满足制药到半导体、结构材料和成像的各行业客户的需要。
Alfa Aesar的主要产品包括:
Chemicals (32249)
Education (2205)
Life Sciences (1463)
Diagnostic Tests and Clinical Products (1213)
Cell Culture (255)
Electrophoresis, Western Blotting and ELISA (113)
Testing and Filtration (88)
Healthcare (80)
Thermometers, pH Meters, Timers and Clocks (70)
Beakers, Bottles, Cylinders and Glassware (63)
Spatulas, Forceps and Utensils (33)
Wipes, Towels and Cleaning (31)
Histology and Cytology (26)
Dishes, Plates and Flasks (18)
Production (15)
Balances, Scales and Weighing (14)
Desiccation and Evaporation (14)
Spectrophotometers, Refractometers and Benchtop Instruments (13)
Chromatography (11)
Gloves, Glasses and Safety (9)
Sonicators, Homogenizers and Blenders (8)
Pumps and Tubing (5)
Instrument Lamps, Lighting and Electrical (4)
Microscopes, Slides and Coverslips (4)
Clamps, Stands and Supports (2)
Test Tubes, Vials, Caps and Closures (2)
Animal Research (1)
Filtration (1)
Incubators, Hot Plates, Baths and Heating (1)
Mixers, Shakers and Stirrers (1)
" data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Alfa Aesar"> Alfa Aesar
艾美捷科技代理Badrilla 品牌。
Badrilla公司拥有一支由经验丰富的科学家和工程师组成的研发团队,他们在心血管研究领域具有深厚的专业知识和丰富的实践经验,特别是蛋白质S-棕榈酰化在疾病中的作用,并确保在您的实验系统中准确、精确和可靠地测量生物标志物浓度。Badrilla公司的主要产品包括用于心血管研究的各种高质量试剂和工具。这些产品旨在帮助研究人员深入了解心血管系统的生理和病理过程,从而推动心血管疾病的治疗和预防。
具体来说,Badrilla公司的产品和服务可能涵盖以下几个方面:
(1)蛋白质研究工具:提供高质量的蛋白质试剂,帮助研究人员研究蛋白质的结构和功能,以及蛋白质在心血管疾病中的作用。
(2)心血管研究试剂:包括用于研究心肌兴奋-收缩耦联、心律失常、心肌肥大和心脏衰竭等心血管疾病的试剂。
(3)定制服务:根据研究人员的具体需求,提供定制化的试剂和服务,以满足其独特的研究需求。
<<< " data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Badrilla品牌"> 艾美捷科技代理Badrilla品牌

艾美捷科技代理BioLab Assays 品牌。
BioLab Assays Ltd.开发、制造和销售创新和原创的即用ELISA(酶联免疫吸附测定)试剂盒。其产品组合包括固相96孔ELISA,设计用于定量测量细胞因子、急性反应物蛋白或趋化因子,并针对血清、血浆、尿液、唾液或脑脊液样品进行了优化。BioLab Assays公司产品涵盖以下领域:肥胖,IR,代谢综合征,糖尿病,肾脏疾病,肺部疾病,动物护理和研究,骨代谢,炎症和感染。
<BioLab Assays公司提供的产品和服务主要包括:
(1)即用型ELISA试剂盒:这是公司的核心产品,用于定量测量各种生物标志物,如细胞因子、急性反应物蛋白、趋化因子等。
(2)定制免疫检测开发:公司还提供定制免疫检测开发服务,以满足客户的特定需求。
(3)合同制造服务:除了自主开发和销售产品外,BioLab Assays公司还提供合同制造服务,为其他公司提供高质量的免疫检测产品。

艾美捷科技代理BBI Solutions品牌诊断原料。
BBI Solutions的产品范围广泛,包括人的抗原、抗体、血清、血浆和临床化学酶等优质原料,还生产世界知名的ELISA试剂盒、生物传感器的标签、黄金纳米粒子和葡萄糖氧化酶等。BBI Solutions提供一系列专业的服务,包括抗体开发、抗体制造、抗原定制、金共轭化等。其独特的抗体开发、侧向流动试验开发和制造服务组合,能够支持客户从概念到商业化的全过程。BBI Solutions拥有专业的研究团队和完善的生产和质控流程,确保了公司产品的高品质。其提供的技术支持涵盖了产品的应用验证、配对使用抗体的推荐等方面,为客户提供了全方位的技术保障。BBI Solutions公司提供试剂专用酶:辣根过氧化物酶、谷氨酸脱氢酶、碱性磷酸酶、尿素酶、胆固醇酯酶,聚链霉亲和素,人源蛋白,单克隆抗体,金纳米颗粒等。
<<< " data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理BBI Solutions品牌诊断原料"> 艾美捷科技代理BBI Solutions品牌诊断原料

艾美捷科技有限公司代理SIRIUS FINE CHEMICALS SICHEM GMBH公司产品。
SIRIUS FINE CHEMICALS SICHEM GMBH公司,主要提供:
点击化学工具(Si-CLICK (Click Chemistry))
PEG试剂(Si-PEGs)
脂质及其衍生物(Si-LIPs (Lipids & Derivatives))
磷酸肌醇试剂(Inositol Phosphates & Phosphoinositides)
核酸及其衍生物(Nucleotides & Derivatives)
API标准品及代谢底物(API Standards & Metabolites)
稳定的同位素(Stable Isotopes)
磷酸化及亚磷酸化试剂(Phosphorylation / Phosphitylation)
精细化学试剂(Fine Chemicals)
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
产品列表
| 产品名称 | 产品编号 | 分子式 |
| Click Amino Acid / trans-Cyclooct-4-en – L - Lysine (TCO4/EQ) / EQUATORIAL isomer | SC-8060 | C15H26N2O4 |
| bifunctional Cross-Linking-Amino-Acid / PrDiAzK | SC-8028 | C13H20N4O5 |
| Click Amino Acid / exo-BCN – Fmoc – L - Lysine (BCN) | SC-8038 | C32H36N2O6 |
| Cross-Linking-Amino-Acid / DiAzK | SC-8034 | C11H20N4O4 |
| Click-Amino-Acid / N3-Lys | SC-8027 | C9H17N5O4 |
| Click Amino Acid / cyclopropene – L - Lysine (CP) | SC-8017 | C12H20N2O4 |
| Click Amino Acid / endo-BCN – Fmoc – L - Lysine (BCN) | SC-8015 | C32H36N2O6 |
| Click Amino Acid / trans-Cyclooct-2-en – L - Lysine (TCO*A) | SC-8008 | C15H26N2O4 |
| Click Amino Acid / exo BCN - L - Lysine | SC-8016 | C17H26N2O4 |
| Click Amino Acid / Norbonene-CH2 – L - Lysine (NBO) | SC-8006 | C15 H24 N2 O4 * HCl |
| Click Amino Acid / rac BCN - L - Lysine | SC-8003 | C17H26N2O4 |
| Click Amino Acid / trans-Cyclooct-4-en – L - Lysine (TCO4) / AXIAL isomer | SC-8004 | C15H26N2O4 |
| Click Amino Acid / endo BCN - L - Lysine | SC-8014 | C17H26N2O4 |
| Click-Amino-Acid / PrK - HCl-salt | SC-8002 | C10H16N2O4 * HCl |
| Click Amino Acid (99%) / SCO - L - Lysine - HCO2H-salt | SC-8001 | C15H24N2O4* HCO2H |
| Click Amino Acid (95%) / SCO - L - Lysine - HCO2H-salt | SC-8000 | C15H24N2O4 * HCO2H |
| SCO-NHS carbonate | SC-8076 | C13H15NO5 |
| exo-BCN-NHS carbonate | SC-8075 | C15H17NO5 |
| endo-BCN-NHS carbonate | SC-8074 | C15H17NO5 |
| SCO-PEG7-Maleimide | SC-8305 | C32H51N3O12 |
| SCO-PEG3-Maleimide | SC-8304 | C24H35N3O8 |
| SCO-PEG2-Maleimide | SC-8303 | C22H31N3O7 |
| BCN-exo-PEG7-Maleimide | SC-8205 | C34H53N3O12 |
| BCN-exo-PEG3-Maleimide | SC-8204 | C24H33N3O7 |
| BCN-exo-PEG2-Maleimide | SC-8203 | C24H33N3O7 |
| BCN-endo-PEG7-Maleimide | SC-8105 | C34H53N3O12 |
| BCN-endo-PEG3-Maleimide | SC-8104 | C24H33N3O7 |
| BCN-endo-PEG2-Maleimide | SC-8103 | C24H33N3O7 |
| BCN-exo-PEG8-COOH | SC-8211 | C30H51NO12 |
| BCN-exo-PEG4-COOH | SC-8210 | C22H35NO8 |
| BCN-exo-PEG3-COOH | SC-8209 | C20H31NO7 |
| BCN-exo-PEG8-NHS | SC-8208 | C34H54N2O14 |
| BCN-exo-PEG4-NHS | SC-8207 | C26H38N2O10 |
| BCN-exo-PEG3-NHS | SC-8206 | C24H34N2O9 |
| BCN-endo-PEG3-NHS | SC-8106 | C24H34N2O9 |
| BCN-endo-PEG4-NHS | SC-8107 | C26H38N2O10 |
| BCN-endo-PEG8-NHS | SC-8108 | C34H54N2O14 |
| BCN-endo-PEG8-COOH | SC-8111 | C30H51NO12 |
| BCN-endo-PEG4-COOH | SC-8110 | C22H35NO8 |
| BCN-endo-PEG3-COOH | SC-8109 | C20H31NO7 |
| SCO-PEG3-COOH | SC-8309 | C18H29NO7 |
| SCO-PEG4-COOH | SC-8310 | C20H33NO8 |
| SCO-PEG8-COOH | SC-8311 | C28H49NO12 |
| SCO-PEG8-NHS | SC-8308 | C32H52N2O14 |
| SCO-PEG4-NHS | SC-8307 | C24H36N2O10 |
| SCO-PEG3-NHS | SC-8306 | C22H32N2O9 |
| SCO-PEG7-NH2 | SC-8302 | C25H46N2O9 |
| SCO-PEG3-NH2 | SC-8301 | C17H30N2O5 |
| SCO-PEG2-NH2 | SC-8300 | C15H26N2O4 |
| BCN-exo-PEG2-NH2 | SC-8200 | C17H28N2O4 |
| BCN-exo-PEG3-NH2 | SC-8201 | C19H32N2O5 |
| BCN-exo-PEG7-NH2 | SC-8202 | C27H48N2O9 |
| BCN-endo-PEG7-NH2 | SC-8102 | C27H48N2O9 |
| BCN-endo-PEG3-NH2 | SC-8101 | C19H32N2O5 |
| BCN-endo-PEG2-NH2 | SC-8100 | C17H28N2O4 |
| exo BCN - OH | SC-8033 | C10 H14 O |
| SCO - active ester (p-NPE) | SC-8032 | C15H15NO5 |
| SCO - OH | SC-8030 | C8H12O |
| endo BCN - OH | SC-8029 | C10 H14 O |
| exo BCN - active ester (p-NPE) | SC-8010 | C17H17NO5 |
| TCO4 - NHS carbonate / EQUATORIAL isomer | SC-8073 | C13H17NO5 |
| TCO4 - NHS carbonate / AXIAL isomer | SC-8072 | C13H17NO5 |
| (E)-cyclooct-4-enol / axial - TCO4 / A | SC-8018 | C8H14O |
| TCO4-PEG8-COOH | SC-8411 | C28H51NO12 |
| TCO*-PEG8-COOH | SC-8511 | C28H51NO12 |
| TCO*-PEG4-COOH | SC-8510 | C20H35NO8 |
| TCO4-PEG4-COOH | SC-8410 | C20H35NO8 |
| TCO4-PEG3-COOH | SC-8409 | C18H31NO7 |
| TCO*-PEG3-COOH | SC-8509 | C20H31NO7 |
| TCO*-PEG8-NHS | SC-8508 | C32H54N2O14 |
| TCO4-PEG8-NHS | SC-8408 | C32H54N2O14 |
| TCO4-PEG4-NHS | SC-8407 | C24H38N2O10 |
| TCO*-PEG4-NHS | SC-8507 | C24H38N2O10 |
| TCO*-PEG3-NHS | SC-8506 | C22H34N2O9 |
| TCO4-PEG3-NHS | SC-8406 | C22H34N2O9 |
| TCO*-PEG7-Maleimide | SC-8505 | C32H53N3O12 |
| TCO*-PEG3-Maleimide | SC-8504 | C24H37N3O8 |
| TCO*-PEG2-Maleimide | SC-8503 | C22H33N3O7 |
| TCO4-PEG7-Maleimide | SC-8405 | C32H53N3O12 |
| TCO4-PEG3-Maleimide | SC-8404 | C24H37N3O8 |
| TCO4-PEG2-Maleimide | SC-8403 | C22H33N3O7 |
| TCO*-PEG2-NH2 | SC-8500 | C15H28N2O4 |
| TCO*-PEG3-NH2 | SC-8501 | C17H32N2O5 |
| TCO*-PEG7-NH2 | SC-8502 | C25H48N2O9 |
| TCO4-PEG7-NH2 | SC-8402 | C25H48N2O9 |
| TCO4-PEG3-NH2 | SC-8401 | C17H32N2O5 |
| TCO4-PEG2-NH2 | SC-8400 | C15H28N2O4 |
| (E)-cyclooct-4-en active ester / TCO/E- active ester (p-NPE) / equatorial | SC-8024 | C15H17NO5 |
| (E)-cyclooct-4-en active ester / TCO4 / A- active ester (p-NPE) / axial | SC-8019 | C15H17NO5 |
| TCO*A - active ester (p-NPE) | SC-8007 | C15H17NO5 |
| Fluorescent-PEG8-Me-Tet | SC-8817 | C54H68N8O13 |
| Fluorescent-PEG4-Me-Tet | SC-8816 | C46H52N8O9 |
| Fluorescent-PEG3-Me-Tet | SC-8815 | C44H48N8O8 |
| Me-Tet-PEG8-NHBoc | SC-8820 | C34H56N6O11 |
| Me-Tet-PEG4-NHBoc | SC-8819 | C26H40N6O7 |
| Me-Tet-PEG3-NHBoc | SC-8818 | C24H36N6O6 |
| Biotin-PEG8-Me-Tet | SC-8814 | C39H62N8O11S |
| Biotin-PEG4-Me-Tet | SC-8813 | C31H46N8O7S |
| Biotin-PEG3-Me-Tet | SC-8812 | C29H42N8O6S |
| Me-Tet-PEG9-COOH | SC-8811 | C32H51N5O12 |
| Me-Tet-PEG5-COOH | SC-8810 | C24H35N5O8 |
| Me-Tet-PEG4-COOH | SC-8809 | C22H31N5O7 |
| Me-Tet-PEG9-NHS | SC-8808 | C36H54N6O14 |
| Me-Tet-PEG5-NHS | SC-8807 | C28H38N6O10 |
| Me-Tet-PEG4-NHS | SC-8806 | C26H34N6O9 |
| Me-Tet-PEG8-Maleimide | SC-8805 | C36H53N7O12 |
| Me-Tet-PEG4-Maleimide | SC-8804 | C28H37N7O8 |
| Me-Tet-PEG3-Maleimide | SC-8803 | C26H33N7O7 |
| Me-Tet-PEG8-NH2 - HCl salt | SC-8802 | C29H48N6O9 + HCl |
| Me-Tet-PEG4-NH2 | SC-8801 | C21H32N6O5 |
| Me-Tet-PEG3-NH2 | SC-8800 | C19H28N6O4 |
| Aminopentyl - Tetrazine - HCl-salt | SC-1193 | C18H20N8O * HCl |
| Tetrazine active ester (Tetrazine-NHS) | SC-1194 | C17H11N7O4 |
| Aminopropyl - Tetrazine - HCl-salt | SC-1192 | C16H16N8O * HCl |
| Methyl-Tetrazine - Amine- HCO2H-salt | SC-1191 | C10H11N5* HCO2H |
| Tetrazine - Amine - HCO2H-salt | SC-1190 | C9H9N5 * HCO2H |
| N3-PEG8-t-butyl ester | SC-8923 | C23H45N3O10 |
| N3-PEG5-t-butyl ester | SC-8922 | C17H33N3O7 |
| N3-PEG4-t-butyl ester | SC-8921 | C15H29N3O6 |
| N3-PEG3-t-butyl ester | SC-8920 | C13H25N3O5 |
| Boc-N-Amido-PEG7-N3 | SC-8912 | C21H42N4O9 |
| Boc-N-Amido-PEG3-N3 | SC-8911 | C13H26N4O5 |
| Boc-N-Amido-PEG2-N3 | SC-8910 | C11H22N4O4 |
| Boc-N-Amido-PEG4-Alkyne | SC-8900 | C16H29NO6 |
| Boc-N-Amido-PEG3-Alkyne | SC-8039 | C14H25NO5 |
| TAMRA-PEG8-Alkyne | SC-8717 | C44H57N3O12 |
| TAMRA-PEG4-Alkyne | SC-8716 | C36H41N3O8 |
| TAMRA-PEG3-Alkyne | SC-8715 | C34H37N3O7 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG2-N3 | SC-8612 | C16H28N6O4S |
| Click-Amino-Acid / PrK - HCl-salt | SC-8002 | C10H16N2O4 * HCl |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| Azido - PEG1 | SC-0062 | C4H9N3O2 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Alkyne - PEG2 - TCA | SC-0067 | C9H12Cl3NO3 |
| Alkyne - PEG2 - CM | SC-0065 | C8H13ClO3 |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG3-CoenzymeA | SC-8618 | C46H75N12O24P3S2+3NH3 |
| Bis-Cyano-PEG9 | SC-8932 | C22H40N2O9 |
| Bis-Cyano-PEG5 | SC-8931 | C14H24N2O5 |
| Bis-Cyano-PEG4 | SC-8930 | C12H20N2O4 |
| N3-PEG8-t-butyl ester | SC-8923 | C23H45N3O10 |
| N3-PEG5-t-butyl ester | SC-8922 | C17H33N3O7 |
| N3-PEG4-t-butyl ester | SC-8921 | C15H29N3O6 |
| N3-PEG3-t-butyl ester | SC-8920 | C13H25N3O5 |
| Boc-N-Amido-PEG7-N3 | SC-8912 | C21H42N4O9 |
| Boc-N-Amido-PEG3-N3 | SC-8911 | C13H26N4O5 |
| Boc-N-Amido-PEG2-N3 | SC-8910 | C11H22N4O4 |
| Boc-N-Amido-PEG4-Alkyne | SC-8900 | C16H29NO6 |
| Boc-N-Amido-PEG3-Alkyne | SC-8039 | C14H25NO5 |
| Fluorescent-PEG8-Me-Tet | SC-8817 | C54H68N8O13 |
| Fluorescent-PEG4-Me-Tet | SC-8816 | C46H52N8O9 |
| Fluorescent-PEG3-Me-Tet | SC-8815 | C44H48N8O8 |
| TAMRA-PEG8-Alkyne | SC-8717 | C44H57N3O12 |
| TAMRA-PEG4-Alkyne | SC-8716 | C36H41N3O8 |
| TAMRA-PEG3-Alkyne | SC-8715 | C34H37N3O7 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| TAMRA-PEG8-COOH | SC-8711 | C44H59N3O14 |
| TAMRA-PEG4-COOH | SC-8710 | C36H43N3O10 |
| TAMRA-PEG3-COOH | SC-8709 | C34H39N3O9 |
| TAMRA-PEG8-NHS | SC-8708 | C48H62N4O16 |
| TAMRA-PEG4-NHS | SC-8707 | C40H46N4O12 |
| TAMRA-PEG3-NHS | SC-8706 | C38H42N4O11 |
| TAMRA-PEG7-Maleimide | SC-8705 | C48H61N5O14 |
| TAMRA-PEG3-Maleimide | SC-8704 | C40H45N5O10 |
| TAMRA-PEG2-Maleimide | SC-8703 | C38H41N5O9 |
| TAMRA-PEG7-NH2 | SC-8702 | C41H56N4O11 |
| TAMRA-PEG3-NH2 | SC-8701 | C33H40N4O7 |
| TAMRA-PEG2-NH2 | SC-8700 | C31H36N4O6 |
| Me-Tet-PEG8-NHBoc | SC-8820 | C34H56N6O11 |
| Me-Tet-PEG4-NHBoc | SC-8819 | C26H40N6O7 |
| Me-Tet-PEG3-NHBoc | SC-8818 | C24H36N6O6 |
| Biotin-PEG8-Me-Tet | SC-8814 | C39H62N8O11S |
| Biotin-PEG4-Me-Tet | SC-8813 | C31H46N8O7S |
| Biotin-PEG3-Me-Tet | SC-8812 | C29H42N8O6S |
| Me-Tet-PEG9-COOH | SC-8811 | C32H51N5O12 |
| Me-Tet-PEG5-COOH | SC-8810 | C24H35N5O8 |
| Me-Tet-PEG4-COOH | SC-8809 | C22H31N5O7 |
| Me-Tet-PEG9-NHS | SC-8808 | C36H54N6O14 |
| Me-Tet-PEG5-NHS | SC-8807 | C28H38N6O10 |
| Me-Tet-PEG4-NHS | SC-8806 | C26H34N6O9 |
| Me-Tet-PEG8-Maleimide | SC-8805 | C36H53N7O12 |
| Me-Tet-PEG4-Maleimide | SC-8804 | C28H37N7O8 |
| Me-Tet-PEG3-Maleimide | SC-8803 | C26H33N7O7 |
| Me-Tet-PEG8-NH2 - HCl salt | SC-8802 | C29H48N6O9 + HCl |
| Me-Tet-PEG4-NH2 | SC-8801 | C21H32N6O5 |
| Me-Tet-PEG3-NH2 | SC-8800 | C19H28N6O4 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG2-N3 | SC-8612 | C16H28N6O4S |
| Biotin-PEG8-COOH | SC-8611 | C29H53N3O12S |
| Biotin-PEG4-COOH | SC-8610 | C19H33N3O7S |
| Biotin-PEG3-COOH | SC-8609 | C19H33N3O7S |
| Biotin-PEG8-NHS | SC-8608 | C33H56N4O14S |
| Biotin-PEG4-NHS | SC-8607 | C25H40N4O10S |
| Biotin-PEG3-NHS | SC-8606 | C23H36N4O9S |
| Biotin-PEG7-Maleimide | SC-8605 | C33H55N5O12S |
| Biotin-PEG3-Maleimide | SC-8604 | C25H39N5O8S |
| Biotin-PEG2-Maleimide | SC-8603 | C23H35N5O7S |
| Biotin-PEG7-NH2 | SC-8602 | C26H50N4O9S |
| Biotin-PEG3-NH2 | SC-8601 | C18H34N4O5S |
| Biotin-PEG2-NH2 | SC-8600 | C16H30N4O4S |
| TCO4-PEG8-COOH | SC-8411 | C28H51NO12 |
| TCO*-PEG8-COOH | SC-8511 | C28H51NO12 |
| TCO*-PEG4-COOH | SC-8510 | C20H35NO8 |
| TCO4-PEG4-COOH | SC-8410 | C20H35NO8 |
| TCO4-PEG3-COOH | SC-8409 | C18H31NO7 |
| TCO*-PEG3-COOH | SC-8509 | C20H31NO7 |
| TCO*-PEG8-NHS | SC-8508 | C32H54N2O14 |
| TCO4-PEG8-NHS | SC-8408 | C32H54N2O14 |
| TCO4-PEG4-NHS | SC-8407 | C24H38N2O10 |
| TCO*-PEG4-NHS | SC-8507 | C24H38N2O10 |
| TCO*-PEG3-NHS | SC-8506 | C22H34N2O9 |
| TCO4-PEG3-NHS | SC-8406 | C22H34N2O9 |
| TCO*-PEG7-Maleimide | SC-8505 | C32H53N3O12 |
| TCO*-PEG3-Maleimide | SC-8504 | C24H37N3O8 |
| TCO*-PEG2-Maleimide | SC-8503 | C22H33N3O7 |
| TCO4-PEG7-Maleimide | SC-8405 | C32H53N3O12 |
| TCO4-PEG3-Maleimide | SC-8404 | C24H37N3O8 |
| TCO4-PEG2-Maleimide | SC-8403 | C22H33N3O7 |
| TCO*-PEG2-NH2 | SC-8500 | C15H28N2O4 |
| TCO*-PEG3-NH2 | SC-8501 | C17H32N2O5 |
| TCO*-PEG7-NH2 | SC-8502 | C25H48N2O9 |
| TCO4-PEG7-NH2 | SC-8402 | C25H48N2O9 |
| TCO4-PEG3-NH2 | SC-8401 | C17H32N2O5 |
| TCO4-PEG2-NH2 | SC-8400 | C15H28N2O4 |
| SCO-PEG7-Maleimide | SC-8305 | C32H51N3O12 |
| SCO-PEG3-Maleimide | SC-8304 | C24H35N3O8 |
| SCO-PEG2-Maleimide | SC-8303 | C22H31N3O7 |
| BCN-exo-PEG7-Maleimide | SC-8205 | C34H53N3O12 |
| BCN-exo-PEG3-Maleimide | SC-8204 | C24H33N3O7 |
| BCN-exo-PEG2-Maleimide | SC-8203 | C24H33N3O7 |
| BCN-endo-PEG7-Maleimide | SC-8105 | C34H53N3O12 |
| BCN-endo-PEG3-Maleimide | SC-8104 | C24H33N3O7 |
| BCN-endo-PEG2-Maleimide | SC-8103 | C24H33N3O7 |
| BCN-exo-PEG8-COOH | SC-8211 | C30H51NO12 |
| BCN-exo-PEG4-COOH | SC-8210 | C22H35NO8 |
| BCN-exo-PEG3-COOH | SC-8209 | C20H31NO7 |
| BCN-exo-PEG8-NHS | SC-8208 | C34H54N2O14 |
| BCN-exo-PEG4-NHS | SC-8207 | C26H38N2O10 |
| BCN-exo-PEG3-NHS | SC-8206 | C24H34N2O9 |
| BCN-endo-PEG3-NHS | SC-8106 | C24H34N2O9 |
| BCN-endo-PEG4-NHS | SC-8107 | C26H38N2O10 |
| BCN-endo-PEG8-NHS | SC-8108 | C34H54N2O14 |
| BCN-endo-PEG8-COOH | SC-8111 | C30H51NO12 |
| BCN-endo-PEG4-COOH | SC-8110 | C22H35NO8 |
| BCN-endo-PEG3-COOH | SC-8109 | C20H31NO7 |
| SCO-PEG3-COOH | SC-8309 | C18H29NO7 |
| SCO-PEG4-COOH | SC-8310 | C20H33NO8 |
| SCO-PEG8-COOH | SC-8311 | C28H49NO12 |
| SCO-PEG8-NHS | SC-8308 | C32H52N2O14 |
| SCO-PEG4-NHS | SC-8307 | C24H36N2O10 |
| SCO-PEG3-NHS | SC-8306 | C22H32N2O9 |
| SCO-PEG7-NH2 | SC-8302 | C25H46N2O9 |
| SCO-PEG3-NH2 | SC-8301 | C17H30N2O5 |
| SCO-PEG2-NH2 | SC-8300 | C15H26N2O4 |
| BCN-exo-PEG2-NH2 | SC-8200 | C17H28N2O4 |
| BCN-exo-PEG3-NH2 | SC-8201 | C19H32N2O5 |
| BCN-exo-PEG7-NH2 | SC-8202 | C27H48N2O9 |
| BCN-endo-PEG7-NH2 | SC-8102 | C27H48N2O9 |
| BCN-endo-PEG3-NH2 | SC-8101 | C19H32N2O5 |
| BCN-endo-PEG2-NH2 | SC-8100 | C17H28N2O4 |
| PEG-12 | SC-1512 | C24H50O13 |
| PEG-11 | SC-1511 | C22H46O12 |
| PEG-10 | SC-1510 | C20H42O11 |
| PEG-9 | SC-1509 | C18H38O10 |
| PEG-8 | SC-1508 | C16H34O9 |
| Alkyne - PEG2 - TCA | SC-0067 | C9H12Cl3NO3 |
| Azido - PEG2 - TCA | SC-0066 | C6H9Cl3N4O2 |
| Alkyne - PEG2 - CM | SC-0065 | C8H13ClO3 |
| Azido - PEG2 - CM | SC-0064 | C5H10ClN3O |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| Azido - PEG1 | SC-0062 | C4H9N3O2 |
| 2-Methyl-Glycerol | SC-0006 | C4H10O3 |
| 2-Stearoyl glycerol | SC-1171 | C21H42O4 |
| 2-Palmitoyl glycerol | SC-1170 | C19H38O4 |
| 2-Myristoyl glycerol | SC-1169 | C17H34O4 |
| 2-Lauroyl glycerol | SC-1168 | C15H30O4 |
| 2-Linoleoyl glycerol | SC-1167 | C21H38O4 |
| 2-Oleoyl-glycerol | SC-1162 | C21H40O4 |
| SH-6 | SC-0045 | C28H57O9P |
| SH-5 | SC-0044 | C29H59O10P |
| Ins(345)P3*3Na | 3-0-345-Na | C6H12Na3O15P3 |
| Ins(1)P*2K | 1-0-1-2K | C6H11K2O9P |
| myo-Inositol – trispyrophosphate | Pyro-Ins-Na | C6H8Na4O21P6 |
| Ins(123456)P6 | 6-0-123456-Na | C6H18O24P6 * xNa*yH2O |
| Ins(23456)P5*10Na | 5-0-23456-Na | C6H7Na10O21P5 |
| Ins(13456)P5*10Na | 5-0-13456-Na | C6H7Na10O21P5 |
| Ins(12456)P5*10Na | 5-0-12456-Na | C6H7Na10O21P5 |
| Ins(12356)P5*10Na | 5-0-12356-Na | C6H7Na10O21P5 |
| Ins(12345)P5*10Na | 5-0-12345-Na | C6H7Na10O21P5 |
| Ins(1345)P4*8Na | 4-0-1345-Na | C6H8Na8O18P4 |
| Ins(136)P3*6Na | 3-0-136-Na | C6H9Na6O15P3 |
| Ins(134)P3*6K | 3-0-134-K | C6H9K6O15P3 |
| Ins(345)P3*3K | 3-0-345-K | C6H12K3O15P3 |
| Ins(145)P3*6K | 3-0-145-K | C6H9K6O15P3 |
| Ins(145)P3*3Li | 3-0-145-Li | C6H12Li3O15P3 |
| Ins(145)P3*6Na | 3-0-145-Na | C6H9Na6O15P3 |
| Ins(135)P3*6Na | 3-0-135-6Na | C6H9Na6O15P3 |
| Ins(1245)P4*8Na | 4-0-1245-Na | C6H8Na8O18P4 |
| INO-4995 | INO-4995 | C50H86O35P4 |
| Bt3-Ins(356)P3 / PM | 3-2-356 | C42H69O30P3 |
| Bt3-Ins(346)P3 / PM | 3-2-346 | C42H69O30P3 |
| Bt3-Ins(146)P3 / PM | 3-2-146 | C42H69O30P3 |
| Bt3-Ins(135)P3 / PM | 3-2-135 | C42H69O30P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-10 | C42H64NO31P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-100 | C42H64NO31P3 |
| Bt2-Ins(3456)P4 / PM | 4-2-3456 | C46H76O36P4 |
| Bt2-Ins(1456)P4 / PM | 4-2-1456 | C46H76O36P4 |
| Bt2-Ins(1345)P4 / PM | 4-2-1345 | C46H76O36P4 |
| Bt2-Ins(1356)P4 / AM | 4-1-1356 | C38H60O36P4 |
| Bt3-Ins(356)P3 / AM | 3-1-356 | C36H57O30P3 |
| Bt3-Ins(346)P3 / AM | 3-1-346 | C36H57O30P3 |
| Bt3-Ins(146)P3 / AM | 3-1-146 | C36H57O30P3 |
| Bt3-Ins(134)P3 / AM | 3-1-134 | C36H57O30P3 |
| Bt3-Ins(136)P3 / AM | 3-1-136 | C36H57O30P3 |
| Bt3-Ins(135)P3 / AM | 3-1-135 | C36H57O30P3 |
| Bt3-Ins(145)P3 / AM | 3-1-145 | C36H57O30P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-10 | C42H64NO31P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-100 | C42H64NO31P3 |
| caged-Ins(145)P3O6 | cag-6-145 | C15H18NO19P3Na6 |
| caged-Ins(145)P3 P4 | cag-0-145 | C14H19NO17P3Na3 |
| PtdIns(345)P3 | Ptd-0-345-16 | C41H82O22P4 |
| PtdIns(45)P2 | Ptd-0-45-16 | C41H81O19P3 |
| PtdIns(34)P2 | Ptd-0-34-16 | C41H81O19P3 |
| PtdIns(5)P | Ptd-0-5-16 | C41H80O16P2 |
| PtdIns(4)P | Ptd-0-4-16 | C41H80O16P2 |
| PtdIns(3)P | Ptd-0-3-16 | C41H80O16P2 |
| PtdIns(1)P | Ptd-0-1-16 | C41H79O13P |
| D-myo-Inositol-1,2-O-cyclohexylidene | SC-0088 | C12H20O6 |
| 23:45- diisopropylidene-myo-Inositol | SC-0079 | C12H20O6 |
| 12:56- diisopropylidene-myo-Inositol | SC-0078 | C12H20O6 |
| D-myo-Inositol-2,3-O-cyclohexylidene | SC-0077 | C12H20O6 |
| 1,4-Di-butyryl-23:56-diisopropylidene-myo-Inositol | SC-0076 | C20H32O8 |
| 3,6-Di-butyryl-12:45-diisopropylidene-myo-Inositol | SC-0075 | C20H32O8 |
| 2,3:4,5-Di-O-Iso-1,6-Di-O-Benzyl-Ins | IOB-Ins-2345 | C26H32O6 |
| 1,2:5,6-Di-O-Iso-3,4-Di-O-Benzyl-Ins | IOB-Ins-1256 | C26H32O6 |
| 3,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-3456 | C34H36O6 |
| 1,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-1456 | C34H36O6 |
| DEAC-dUTP | SC-9002 | C26H31N4O17P3 |
| 35-PAPS-TEA | SC-9000-TEA | C10H15N5O13P2S x 4 C6 H15 N |
| ACPPS-TEA | SC-0068 | C10H13N5O12P2S + C6H5N |
| 25-PAPS-Li | SC-9001-Li | C10H11Li4N5O13P2S |
| 35-PAPS-Li (CAS: 102029-54-9) | SC-9000-Li | C10H11Li4N5O13P2S |
| EdU | SC-0040 | C11H12N2O5 |
| EdUTP-TEA | SC-0039 | C11H15N2O14P3 * 4(C6H15N) |
| EdUTP | SC-0038 | C11H15N2O14P3 |
| 2'-PAP | SC-0037 | C10H17N5O10P2 |
| 2'-PAP-Na | SC-0036 | C10H15N5Na2O10P2 |
| 3'-PAP-Na | SC-0034 | C10H15N5Na2O10P2 |
| 3'-PAP | SC-0035 | C10H17N5O10P2 |
| Vancomycin hexapeptide | SC-1606 | C59H62Cl2N8O23 |
| Didechloro Vancomycin | SC-1605 | C66H77N9O24 |
| Vancomycin Impurity A | SC-1601 | C65H73Cl2N9O24 |
| Vancomycin Impurity D | SC-1604 | C59H62Cl2N8O22 |
| Vancomycin Impurity C | SC-1603 | C53H52Cl2N8O17 |
| Vancomycin Impurity B | SC-1602 | C66H74Cl2N8O25 |
| INO-4995 | INO-4995 | C50H86O35P4 |
| Fidaxomicin - d7 | SC-1157 | C52H67D7Cl2O18 |
| Podophyllotoxin Derivate | SC-0025 | C21H20O8 |
| Podophyllotoxin Derivate | SC-0026 | C21H21NO7 |
| Clopidogrel Impurity 4 | SC-0099 | C16H16ClNO2S * H2SO4 |
| Gestodene Impurity E | SC-0028 | C21H24O3 |
| Fidaxomicin Metabolite OP-1118 | SC-1158 | C48H68Cl2O17 |
| Prasugrel metabolite M6-d3 (stabilzed) | SC-0093 | C27H25D3FNO5S * HCl |
| Prasugrel metabolite M6 | SC-0092 | C19H22FNO3S |
| Clopidogrel Impurity C | SC-0087 | C16H18ClNO2S |
| Clopidogrel Impurity 3 | SC-0086 | C15H17Cl2NO2S |
| Prasugrel active metabolite M3-d3 (stabilzed) | SC-0033 | C27H25D3FNO5S * HCl |
| Prasugrel active metabolite M3 HCl (stabilized) | SC-0029 | C27H28FNO5S * HCl |
| Fidaxomicin - d7 | SC-1157 | C52H67D7Cl2O18 |
| Methyl 4-(2-hydroxyethyl)benzoate-13C6,2D (Ring-13C6,Ethyl-1,2-D2) | SC-0080 | C4 13C6 H10 D2 O3 |
| Anthracene 13C6 | SC-0074 | 13C6C8H8 |
| Phenanthrene 13C6 | SC-0073 | 13C6C8H8 |
| Naphthalene 13C10 | SC-0072 | 13C10H8 |
| Naphthalene 13C6 | SC-0071 | 13C6C4H8 |
| Prasugrel active metabolite M3-d3 (stabilzed) | SC-0033 | C27H25D3FNO5S * HCl |
| 2-Cyanoethyl N,N-diisopropylchlorophosphoramidite | SC-0091 | C9H18ClN2OP |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. bis(2-cyanoethyl) ester | SC-0061 | C12H22N3O2P |
| Phosphoramidous acid, N,N-bis(1-methylethyl)-, bis(phenylmethyl) ester | SC-1165 | C20 H28 N O2 P |
| Phosphorodiamidous acid. N.N.N'.N'-tetrakis(1-methylethyl)-. phenylmethyl ester | SC-0060 | C19 H35 N2 O P |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. 2-cyanoethyl [1-(2-nitrophenyl)ethyl] ester) | SC-0059 | C17 H26 N3 O4 P |
| Dichloro N,N-Diisopropylphosphoramidite | SC-0058 | C6 H14 Cl2 N P |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. bis(9H-fluoren-9-ylmethyl) ester | SC-0057 | C34 H36 N O2 P |
| Di-tert-butyl chloromethyl phosphate | SC-0011 | C9H20ClO4P |
| Di-benzyl chloromethyl phosphate | SC-0010 | C15H16ClO4P |
| TMe-OHB-DAZA | SC-0300 | C29H37N3O6 |
| TEt-OHB-DAZA | SC-0301 | C32H43N3O6 |
| NEmo2E | SC-0201 | C96H138KN18O30S |
| NEmo1 | SC-0200 | C96H138KN18O30S |
| D-Serine-O-phosphate | SC-1810 | C3H8NO6P |
| Ph-CCA-NH2 | SC-1400 | C16H12N2O |
| Menaquinone 8 / MK 8:8 | SC-1230 | C51H72O2 |
| Allyl-Maleimide | SC-1121 | C7H7NO2 |
| Nor-cisapride Derivative | SC-1161 | C17H25Cl2N3O3 |
| AlK - L - Lysine - HCl-salt | SC-8012 | C10H18N2O4* HCl |
| 4-methyl-2,2-bis(trifluoromethyl)oxazolidin-5-one | SC-0098 | C6H5F6NO2 |
| 3-(5-oxo-2,2-bis(trifluoromethyl)oxazolidin-4-yl)propanoic acid | SC-0097 | C8H7F6NO4 |
| 7-(diethylamino)-4-(hydroxymethyl)-coumarin / DEACM | SC-0096 | C14H17NO3 |
| 3-bromo-4-methyl-7-(diethylamino)-coumarin | SC-0095 | C14H16BrNO2 |
| Xanthohumol | SC-0094 | C21H22O5 |
| IEPOX 4 | SC-0090 | C5H10O3 |
| IEPOX 3 | SC-0089 | C5H10O3 |
| 2-C-Methyl-L-Threitol | SC-0085 | C5H12O4 |
| 2-C-Methyl-D-Threitol | SC-0084 | C5H12O4 |
| 2-C-Methyl-L-Erythritol | SC-0083 | C5H12O4 |
| 2-C-Methyl-D-Erythritol | SC-0082 | C5H12O4 |
| 3-Amino-7-(diethylamino)-coumarine | SC-0081 | C13 H16 N2 O2 |
| Chloromethylpropionate | SC-1164 | C4H7ClO2 |
| 2-(2-fluoro-2-methylpropoxy)-2-methylpropan-1-ol | SC-1163 | C8H17FO2 |
| 1,4-Di-butyryl-23:56-diisopropylidene-myo-Inositol | SC-0076 | C20H32O8 |
| 3,6-Di-butyryl-12:45-diisopropylidene-myo-Inositol | SC-0075 | C20H32O8 |
| Y-27632 | SC-0048 | C14H21N3O *2HCl |
| H-1152 | SC-0053 | C16H21N3O2S*2HCl |
| 3,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-3456 | C34H36O6 |
| 1,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-1456 | C34H36O6 |
| Biotin-PEG3-CoenzymeA | SC-8618 | C46H75N12O24P3S2+3NH3 |
| TMe-OHB-DAZA | SC-0300 | C29H37N3O6 |
| TEt-OHB-DAZA | SC-0301 | C32H43N3O6 |
| SCO-NHS carbonate | SC-8076 | C13H15NO5 |
| endo-BCN-NHS carbonate | SC-8074 | C15H17NO5 |
| TCO4 - NHS carbonate / EQUATORIAL isomer | SC-8073 | C13H17NO5 |
| TCO4 - NHS carbonate / AXIAL isomer | SC-8072 | C13H17NO5 |
| TCO* - NHS carbonate / EQUATORIAL isomer | SC-8071 | C13H17NO5 |
| TCO* - NHS carbonate / AXIAL isomer | SC-8070 | C13H17NO5 |
| NEmo2E | SC-0201 | C96H138KN18O30S |
| NEmo1 | SC-0200 | C96H138KN18O30S |
| bifunctional Cross-Linking-Amino-Acid / PrDiAzK | SC-8028 | C13H20N4O5 |
| Vancomycin hexapeptide | SC-1606 | C59H62Cl2N8O23 |
| Ph-CCA-NH2 | SC-1400 | C16H12N2O |
| Cross-Linking-Amino-Acid / DiAzK | SC-8034 | C11H20N4O4 |
| PEG-9 | SC-1509 | C18H38O10 |
| PEG-8 | SC-1508 | C16H34O9 |
| Click Amino Acid / cyclopropene – L - Lysine (CP) | SC-8017 | C12H20N2O4 |
<艾美捷科技代理Nanosoftpolymers品牌全系列产品
Nanosoft Polymers(NSP)是一家专注于提供用于治疗、设备和诊断的即用型功能化聚合物和共聚物的企业,旨在弥合聚合物和药物递送之间的差距。NSP生产和销售一系列独特的功能性聚合物、共聚物和聚合物偶联物,其聚合物目录丰富多样,涵盖功能性PLGA - PEG、PLA - PEG、PCL - PEG、脂质PEG、聚(L - 赖氨酸)- PEG、聚(L - 谷氨酸)- PEG和聚乙二醇化试剂等。这些产品可应用于药物/基因递送、封装、细胞粘附和表面修饰等多个研究领域。除了销售现有产品,NSP还专门从事聚合物合成和功能化、纳米颗粒制造、表面改性以及具有广泛分子量范围的反应性低聚物和聚合物的定制合成,能够满足客户多样化的需求。

▍Nanosoftpolymers产品线
● 多糖:是由长链单糖单元通过糖苷键连接而成的高分子碳水化合物,具有良好的生物相容性、无毒性和非免疫原性。
● 抗癌试剂与原料药:提供种类丰富的高品质抗癌试剂与原料药,用于药物研发。
● 脂质:NSP的功能性脂质用于制备脂质体或纳米颗粒,这些脂质体或纳米颗粒可通过脂质头部的官能团进一步进行生物偶联修饰。
● PEI-PEGs:NSP 的 PEI-PEG 聚合物包括 PEG 接枝的支链 PEI和 PEG 偶联的线性PEI,可用于体外和体内将寡核苷酸递送至细胞和组织。
● 聚氨基酸:可提高药物结合物的溶解度和稳定性、药物包封、药物靶向、绕过多药耐药因素、对免疫系统的刺激极小、低毒性以及生物可降解性。
● 脂质 - 聚乙二醇(Lipid-PEGs):提供多样化的脂质及磷脂PEG衍生物,广泛应用于药物递送、脂质体 / 胶束形成、小分子和大分子药物制剂以及表面修饰等领域。
● Poly(amino acid)-PEGs:NSP 的 PEG-PAA 包括聚(L - 赖氨酸)-PEG、聚(L - 谷氨酸)-PEG、聚(L - 天冬氨酸)-PEG 及其功能化共聚物。
● 功能性聚乙二醇:提供多种高品质 PEG 试剂,用于聚乙二醇化、药物递送、生物偶联和表面修饰。NSP 的功能性聚乙二醇包括单线性聚乙二醇、同源双功能聚乙二醇、异源双功能聚乙二醇和多臂聚乙二醇。
● 单体:是一种可通过化学方式或超分子方式与其他分子结合,从而形成(超分子)聚合物的分子。
● 聚酯 - 聚乙二醇(Polyester-PEGs):提供基于聚酯的功能性两亲性嵌段共聚物,如聚乳酸 - 聚乙二醇(PLA-PEG)、聚乳酸 - 羟基乙酸共聚物 - 聚乙二醇(PLGA-PEG)、聚己内酯 - 聚乙二醇(PCL-PEG),用于药物递送研究。
● 按官能团分类的聚合物:包括但不限于:胺基、Boc 或 Fmoc 保护的胺基、羧基、马来酰亚胺基、生物素、叠氮基、巯基、酰肼基、炔基、邻吡啶二硫基(OPSS)、活性琥珀酸酯基、乙烯基砜基(VS)、丙烯酸酯基、硝基苯基碳酸酯基(NPC)、二苯并环辛炔基(DBCO)、叶酸基等。
● 荧光聚合物:提供 “即开即用型” 荧光聚合物,研究人员可借助显微镜或 IVIS 成像技术对聚合物及纳米药物进行追踪。NSP的荧光染料包括罗丹明、荧光素、Cy3、Cy5.0、Cy5.5 及 Cy7 等。
▍Nanosoftpolymers部分产品列表
| 品名 | 货号 | 分子量 | 规格 |
| Hyaluronate Amine | 13390 | 5K, 10K, 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| Hyaluronate Thiol | 24656 | 5K, 10K, 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| Hyaluronic Acid Tetrabutylammonium | 13378 | 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| Methacrylated Hyaluronic Acid (HA-MA) | 13204 | 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| 10-Hydroxycamptothecin | 11999 | 364.35 | 100mg, 500mg, 1g, 5g, 10g |
| 7-Ethyl-10-hydroxycamptothecin | 12007 | 392.4 | 20mg, 100mg, 500mg, 1g |
| Abarelix Acetate | 12014 | 1416.08 | 1mg, 5mg, 10mg, 25mg, 50mg, 100mg |
| Camptothecin | 11992 | 348.35 | 250mg, 500mg, 1g, 5g |
| Cisplatin | 12032 | 300.05 | 100mg, 200mg, 500mg, 1g |
| Cucurbitacin B | 11964 | 558.712 | 5mg, 10mg, 20mg, 50mg, 100mg |
| Cucurbitacin E | 12024 | 556.696 | 1mg, 5mg, 10mg, 25mg |
| Cyclosporine A | 12086 | 1202.61124 | 100mg, 500mg, 1g, 5g, 10g |
| Doxorubicin hydrochloride | 11947 | 579.98 | 50mg, 100mg, 500mg, 1g |
| Irinotecan HCl | 11985 | 677.18 | 20mg, 50mg, 100mg, 500mg |
| Paclitaxel | 11955 | 853.33096 | 50mg, 100mg, 1g, 10g, bulk |
| Topotecan Hydrochloride | 11977 | 457.91 | 20mg, 50mg, 100mg, 500mg |
| β-Lapachone | 12048 | 242.09429 | 10mg, 25mg, 100mg |
| ALC-0315 | 28068 | 766.290 | 50mg, 100mg, 200mg, 1g |
| DLin-KC2-DMA | 27581 | 642.11 | 5mg, 10mg, 25mg, 50mg, 100mg, 200mg |
| DLin-MC3-DMA | 25325 | 642.11 | 50mg, 100mg, 1g, 5g |
| DODAP (18:1) | 26495 | 648.05 | 100mg, 500mg, 1g |
| DODMA | 27967 | 620.104 | 50mg, 100mg, 1g |
| DOTAP (18:1) | 25396 | 698.555 | 100mg, 500mg, 1g |
| DOTMA | 25335 | 670.575 | 50mg, 100mg, 1g |
| DSTAP (18:0) | 26129 | 702.57 | 100mg, 500mg, 1g |
| SM-102 | 27852 | 709.66 | 50mg, 100mg, 200mg, 1g |
| ALC-0315 | 28068 | 766.290 | 50mg, 100mg, 200mg, 1g |
| DLin-KC2-DMA | 27581 | 642.11 | 5mg, 10mg, 25mg, 50mg, 100mg, 200mg |
| DSPC (18:0 PC) | 26737 | 790.145 | 500mg, 1g, 5g |
| DSPE | 13903 | 748.07 | 100mg, 200mg, 500mg, 1g |
| DSPE-Maleimide/DSPE-MAL | 10791 | 898.19 | 50mg, 100mg, 500mg |
| DSTAP (18:0) | 26129 | 702.57 | 100mg, 500mg, 1g |
| SM-102 | 28527 | 709.66 | 50mg, 100mg, 200mg, 1g |

艾美捷科技代理Nordic MUbio品牌产品。
Nordic-MUbio公司为生物医学和兽医研究提供2000多种基本免疫试剂,包括抗血清、抗体、免疫偶联物、纯化蛋白、对照品、血清蛋白标准品和其他校准品。它们包括高度特异性的单克隆抗体,以及用于不同测试系统的偶联二抗试剂。Nordic-MUbio专注于免疫学,拥有超过1700种针对人、小鼠、猴子和大鼠免疫球蛋白类及其亚类的特异性抗血清。此外还有针对不同动物物种的其他血清蛋白多克隆抗血清和针对酶的多克隆抗血清。Nordic-MUbio的抗体也以荧光和辣根过氧化物酶偶联物的形式提供。
" data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Nordic MUbio品牌产品"> 艾美捷科技代理Nordic MUbio品牌产品
艾美捷科技代理Magtivio品牌磁珠产品
荷兰Magtivio BV是一家磁性微/纳米颗粒生产商,为生命科学和生物分析领域提供磁珠及完整试剂盒产品。Magtivio BV设计开发了两种类型的二氧化硅包覆氧化铁磁珠,其中包括:超顺磁
性磁珠,它们采用复合多孔结构设计,易于再悬浮,并表现出较低的沉降率;以及铁磁性磁珠,这些磁珠粒型由相对致密的核壳结构制成,具有强磁性,更适合大体积和粘性样品。末端官能
化的基团可以连接到两种磁珠类型的二氧化硅涂层。Magtivio BV的产品包括:
(1)核酸纯化:MagSi-(D)NA试剂盒和磁珠作为固体支持相,从病原体、植物和动物组织、体液和细胞中分离核酸。
(2)DNA纯化:MagSi试剂盒,用于测序应用中的PCR 纯化、DNA大小选择。
(3)免疫测定:MagSi链霉亲和素珠用作固相,易于结合生物素化的生物分子。
(4)蛋白质分析:具有改性表面的MagSi微珠,用于蛋白质的纯化和分离,用于质谱、蛋白质组学分析和生物标志物研究。
(5)研究工具:表面活化的MagSi微珠,用于固定蛋白质、肽、核酸或其他感兴趣的分子;MagSi 平台具有广泛的功能化可能性。
(6)LCMS样品制备:在LC-MS/MS分析之前,基于MagSiMUS磁珠的生物样品制备,用于蛋白质耗竭和从生物样品中去除其他干扰化合物。
(7)SafeQ:用于样本采集、储存和释放的解决方案,例如唾液采集试剂盒
(8)磁选机:用于从液体样品中磁分离MagSi和MagSiMUS磁珠。
(9)rQ " data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Magtivio品牌磁珠产品">
艾美捷科技代理Magtivio品牌磁珠产品
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理Trialtusbioscience品牌全系列产品
TriAltus Bioscience是一个致力于为推动人类健康前沿的科学家服务的品牌。当今的创新者在推进基因疗法、工程诊断、早期疾病检测以及药物发现等领域,都需要高纯度、高性能且随时可以扩展的酶,TriAltus正是为此而存在。TriAltus的核心是其专有的CLiM™(CL7/Im7)纯化平台,是一种基于亲和标签的突破性系统,能在单个色谱步骤中提供具有卓越纯度、活性和一致性的酶,重新定义了重组蛋白纯化的可能性。 使用CLiM™生产的每种酶都以严格的质量控制、批次间一致性和详细的分析证书(COA)为后盾,旨在满足监管机构要求的质量和文档标准,支持从发现到扩大规模的更平稳过渡。TriAltus Bioscience公司的产品包括:基因组酶、蛋白酶和其他酶。

▍Trialtusbioscience产品线
● 基因组酶:TriAltus的重组基因组酶不含标签,并使用专有的CLiM™亲和标签系统进行纯化,提供目录酶的定制缩放和配方,以满足特定研究需求,无论需要更高的浓度、独特的缓冲条件还是批量生产,都可以根据具体规格定制酶。
| 货号 | 品名 | 规格 | 产品描述 |
| 40-1212 | AapCas12b Protein | 20 μg | expressed in E. coli and features two C-terminal nuclear localization signals,enables the inactive nuclease to be guided to the specific double stranded DNA site. |
| 40-1220 | AapCas12b Protein | 100 μg | |
| 40-1225 | AapCas12b Protein | 500 μg | |
| 40-1320 | CRISPR-Cas9 Protein | 100 μg | used for genome editing with CRISPR technology. Recombinant Streptococcus pyogenes Cas9 ,expressed in Escherichia coli and features two nuclear localization signals |
| 40-1325 | CRISPR-Cas9 Protein | 500 μg | |
| 40-2414 | Phi29 DNA Polymerase | 3,000 Units | a highly processive, isothermal enzyme from Bacillus subtilis phage phi29 ,with a robust 3'→5' proofreading exonuclease function. |
| 40-2420 | Phi29 DNA Polymerase | 10,000 Units | |
| 40-2125 | TAT-CRE Recombinase | 500 μg | used for site-specific DNA recombination in mammalian cells,a fusion protein combining a nuclear localization sequence, HIV-TAT cell permeabilization peptide, and Cre recombinase. |
| 40-2130 | TAT-CRE Recombinase | 1 mg | |
| 40-2135 | TAT-CRE Recombinase | 5 mg |
● 蛋白酶和其他酶:例如为冷冻电镜生成蛋白质的实验室提供SUMO蛋白酶,去除相关标签后蛋白质可进行分析,反应高效、稳健,无需优化,客户对酶的性能和优质客户服务感到满意。
| 货号 | 品名 | 规格 | 产品描述 |
| 30-2130 | PreScission Protease | 1 mg | recognizes and cleaves the sequence LEVLFQ/GP to release the target protein from the Im7-bound CL7 tag |
| 30-2135 | PreScission Protease | 5 mg | |
| 30-2140 | PreScission Protease | 10 mg | |
| 30-2146 | PreScission Protease | 50 mg | |
| 30-2150 | PreScission Protease | 100 mg | |
| 30-1130 | SUMO Protease | 1 mg | releases target proteins from TriAltus’s Im7 resin,recognizes SUMO tertiary structure – not a specific amino acid sequence – to cleave and release the target protein from the Im7-bound CL7 tag. |
| 30-1135 | SUMO Protease | 5 mg | |
| 30-1140 | SUMO Protease | 10 mg | |
| 30-1146 | SUMO Protease | 50 mg | |
| 30-1150 | SUMO Protease | 100 mg |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:15172431432
邮箱:sales@amyjet.com
0.2055